•
Mar 31

Cigna Q1 2025 Earnings Report

The Cigna Group reported strong Q1 2025 results with a significant increase in revenues and a return to profitability.

Key Takeaways

The Cigna Group delivered robust financial results in Q1 2025, with total revenues growing 14% year-over-year to $65.5 billion and net income reaching $1.3 billion. Adjusted income from operations was $1.8 billion, highlighting strong performance across Evernorth Health Services and Cigna Healthcare segments.

Total revenues rose 14% year-over-year to $65.5 billion, driven by strong growth in pharmacy services.

Net income reached $1.3 billion, reversing a net loss of $0.3 billion in Q1 2024.

Adjusted income from operations was $1.8 billion or $6.74 per share.

The company raised its full-year 2025 outlook to at least $29.60 adjusted income per share.

Total Revenue
$65.5B
Previous year: $57.2B
+14.4%
EPS
$6.74
Previous year: $6.47
+4.2%
Adjusted EPS
$6.74
Previous year: $6.47
+4.2%
Customer Relationships
182.21M
Pharmacy Customers
122.28M
Previous year: 118.3M
+3.4%
Total Assets
$146B
Previous year: $148B
-1.5%

Cigna

Cigna

Cigna Revenue by Segment

Forward Guidance

Cigna raised its 2025 outlook, expecting at least $29.60 in adjusted income per share, reflecting confidence in strong segment performance and capital deployment.

Positive Outlook

  • Raised 2025 adjusted EPS guidance to at least $29.60.
  • Expected Evernorth adjusted income from operations to exceed $7.2 billion.
  • Expected Cigna Healthcare adjusted income from operations to exceed $4.125 billion.
  • Continued share repurchases projected to support EPS growth.
  • Anticipated strong performance in pharmacy and specialty services.

Challenges Ahead

  • Higher expected medical costs contributing to elevated MCR.
  • Impact of HCSC divestiture may reduce customer base in near term.
  • Strategic investments may compress near-term operating margins.
  • Lower net investment income compared to prior year.
  • Macroeconomic and regulatory uncertainties could affect growth targets.